* U.S. FDA approves 41 novel medicines in 2014 vs 27 in 2013 * U.S. FDA approves 41 novel medicines in 2014 vs 27 in 2013 * New treatments for cancer and rare disease fuel rise * High cost of new drugs leads to tensions with insurers By Ben Hirschler LONDON, Jan 1 (Reuters) –(…)

Revived markets, inversions, and big pharma’s appetite for new therapies spur megamergers. 2014 could be a year for the history books. Many believe that we will never see another year with so many mergers and acquisitions. [© Yuri Arcurs – Fotolia.com] Just a few numbers show how far the value of 2014’s top deals involving(…)

HBR Blog Network Harvard Business Review by Christine M. Riordan  |   12:00 PM June 5, 2014 Over the past decade, organizations have worked hard to create diversity within their workforce. Diversity can bring many organizational benefits, including greater customer satisfaction, better market position, successful decision-making, an enhanced ability to reach strategic goals, improved organizational outcomes, and a stronger(…)

06-5-2014 |by  EDWARD C LAWRENCE   If you think the pharmaceutical industry’s direct-to-consumer advertising is limited largely to national nightly news broadcasts and geriatric magazines, think again. Brand-name drug manufacturers have gone fully digital, with significant implications for patients, physicians, and public and private payers. While most companies are rushing to implement digital marketing strategies, brand-name pharmaceuticals(…)

MICHAEL H. COHEN, ESQ. – FEB 2014 Sixty years ago, a family with a sick child could call their doctor, and, in a couple of hours, see him or her at the front curb, emerging with the well-known “black bag.” Times have changed, but at least when it comes to convenience, what was old is new again.(…)